ArticlePloS one2016
Host Factors and Biomarkers Associated with Poor Outcomes in Adults with Invasive Pneumococcal Disease.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis.Scientific reports · 2021Pooled it
- Review
- Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012-2022.Emerging microbes & infections · 2025Article
- Burden of Antimicrobial Resistance in Japan: A Systematic Literature Review and Meta-Analysis.Infectious diseases and therapy · 2024Article
- Invasive Pneumococcal Diseases in Korean Adults After the Introduction of Pneumococcal Vaccine into the National Immunization Program.Infection & chemotherapy · 2023Review
- Vaccinating Welders against Pneumococcus: Evidence from a Systematic Review and Meta-Analysis.Vaccines · 2023Review
- Clinical characteristics, antimicrobial resistance, and risk factors for mortality in paediatric invasive pneumococcal disease in Beijing, 2012-2017.BMC infectious diseases · 2022Article
- Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Observational
- Relationship between serotypes, disease characteristics and 30-day mortality in adults with invasive pneumococcal disease.Infection · 2022Article
- A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.Human vaccines & immunotherapeutics · 2020Article
- Factors Associated With Severe Nonmeningitis Invasive Pneumococcal Disease in Adults in France.Open forum infectious diseases · 2019Article
- Observational
- Genome Evolution to Penicillin Resistance in Serotype 3 Streptococcus pneumoniae by Capsular Switching.Antimicrobial agents and chemotherapy · 2017Article
- Correction: Host Factors and Biomarkers Associated with Poor Outcomes in Adults with Invasive Pneumococcal Disease.PloS one · 2016Article
- Clinical characteristics of patients with severe sepsis and septic shock in relation to bacterial virulence of beta-hemolyticAcute medicine & surgeryArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive pneumococcal disease (IPD) causes considerable morbidity and mortality. We aimed to identify host factors and biomarkers associated with poor outcomes in adult patients with IPD in Japan, which has a rapidly-aging population.
methodsIn a large-scale surveillance study of 506 Japanese adults with IPD, we investigated the role of host factors, disease severity, biomarkers based on clinical laboratory data, treatment regimens, and bacterial factors on 28-day mortality.
resultsOverall mortality was 24.1%, and the mortality rate increased from 10.0% in patients aged ˂50 years to 33.1% in patients aged ≥80 years. Disease severity also increased 28-day mortality, from 12.5% among patients with bacteraemia without sepsis to 35.0% in patients with severe sepsis and 56.9% with septic shock. The death rate within 48 hours after admission was high at 54.9%. Risk factors for mortality identified by multivariate analysis were as follows: white blood cell (WBC) count <4000 cells/μL (odds ratio [OR], 6.9; 95% confidence interval [CI], 3.7-12.8, p < .001); age ≥80 years (OR, 6.5; 95% CI, 2.0-21.6, p = .002); serum creatinine ≥2.0 mg/dL (OR, 4.5; 95% CI, 2.5-8.1, p < .001); underlying liver disease (OR, 3.5; 95% CI, 1.6-7.8, p = .002); mechanical ventilation (OR, 3.0; 95% CI, 1.7-5.6, p < .001); and lactate dehydrogenase ≥300 IU/L (OR, 2.4; 95% CI, 1.4-4.0, p = .001). Pneumococcal serotype and drug resistance were not associated with poor outcomes.
conclusionsHost factors, disease severity, and biomarkers, especially WBC counts and serum creatinine, were more important determinants of mortality than bacterial factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.